RxDoctor Payments Data

Dwayne Brown

Neurology · Manahawkin, NJNPI 1760914527

Payments from drug & device makers

$66,509in general payments, 2019–2025

Across 142 payments — averaging $468.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$33K
  • Axsome Therapeutics, Inc.$22K
  • Pfizer$11K
  • Biohaven Pharmaceutical Holding Company Ltd.$125
  • Lundbeck LLC$125
  • Biogen$120
  • plus $188 from 5 others

What the payments were for

  • Consulting fees$1,5252%
  • Speaking & faculty fees$60,70391%
  • Travel & lodging$2070%
  • Food & beverage$4,0736%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)99$32,818
Axsome Therapeutics, Inc.16$21,658
Pfizer15$11,476
Biohaven Pharmaceutical Holding Company Ltd.1$125
Lundbeck LLC1$125
Biogen2$120
Amgen1$83
Neurocrine Biosciences, Inc.3$54
Lilly USA, LLC2$31
Bristol Myers Squibb1$17
Impel Pharmaceuticals LLC1$4

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,509 in reported general payments places this provider in the 85th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$38,532
Medicare patients
125
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant248$374,696
QuliptaAtogepant333$352,091
Nurtec OdtRimegepant Sulfate73$130,113
BotoxOnabotulinumtoxina100$123,702
Aimovig AutoinjectorErenumab-Aooe84$65,940
Ajovy AutoinjectorFremanezumab-Vfrm31$22,511
ZavzpretZavegepant Hcl19$20,218
Emgality PenGalcanezumab-Gnlm16$11,518
Sumatriptan Succinate89$3,019
Gabapentin181$1,731
Candesartan Cilexetil13$879
RizatriptanRizatriptan Benzoate57$770
Topiramate68$708
Naratriptan Hcl47$665
Baclofen11$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$32,818$850,489681 claims
PfizerNurtec Odt, Zavzpret$11,476$150,33192 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 521 neurology providers in New Jersey.

Other neurology in Manahawkin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →